Lv3
302 积分 2024-09-27 加入
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response
1天前
待确认
Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy
5天前
已完结
Antibody screening for tumor and immune hotspot targets: The frontier of new methods and technologies
7天前
已完结
A Sampling of Highlights from the Literature
7天前
已完结
Development and Application of a Single Cell-Level PK-PD Model for ADCs
11天前
已完结
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
12天前
已完结
Recent development of ATR inhibitors for cancer therapy
18天前
已完结
P2.10.17 Dual PARG-TOP1 Inhibition Exacerbates Dna-Protein Crosslinks and Replication Stress: A Promising Strategy for Enhancing Top1i-ADC Efficacy
18天前
已关闭
Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates
18天前
已完结
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
18天前
已完结
皖公网安备34019202002308
